Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New anxiety drug shows promise in early trial

NCT ID NCT06051721

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 27 times

Summary

This study tests a new drug called CYB004 in 36 adults with moderate to severe generalized anxiety disorder (GAD). The goal is to see if it safely reduces anxiety symptoms compared to an active control. Participants must be on a stable dose of their current anxiety medication. The trial is in phase 2a, meaning it's early but looking for signs of effectiveness.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED ANXIETY DISORDER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Cedar Clinical Research

    Murray, Utah, 84107, United States

  • CenExel ACMR

    Atlanta, Georgia, 30331, United States

  • Innovative Clinical Research, Inc.

    Miami Lakes, Florida, 33016, United States

  • Research Centers of America

    Hollywood, Florida, 33024, United States

  • Uptown Research Institute

    Chicago, Illinois, 60640, United States

  • iResearch Atlanta

    Decatur, Georgia, 30330, United States

Conditions

Explore the condition pages connected to this study.